678 related articles for article (PubMed ID: 17352936)
1. Selective degeneration in YAC mouse models of Huntington disease.
Van Raamsdonk JM; Warby SC; Hayden MR
Brain Res Bull; 2007 Apr; 72(2-3):124-31. PubMed ID: 17352936
[TBL] [Abstract][Full Text] [Related]
2. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Murphy Z; Slow EJ; Leavitt BR; Hayden MR
Hum Mol Genet; 2005 Dec; 14(24):3823-35. PubMed ID: 16278236
[TBL] [Abstract][Full Text] [Related]
3. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration.
Hodgson JG; Agopyan N; Gutekunst CA; Leavitt BR; LePiane F; Singaraja R; Smith DJ; Bissada N; McCutcheon K; Nasir J; Jamot L; Li XJ; Stevens ME; Rosemond E; Roder JC; Phillips AG; Rubin EM; Hersch SM; Hayden MR
Neuron; 1999 May; 23(1):181-92. PubMed ID: 10402204
[TBL] [Abstract][Full Text] [Related]
4. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus vector-based in vitro neuronal cell model for Huntington's disease with human disease-like differential aggregation and degeneration.
Dong X; Zong S; Witting A; Lindenberg KS; Kochanek S; Huang B
J Gene Med; 2012 Jul; 14(7):468-81. PubMed ID: 22700462
[TBL] [Abstract][Full Text] [Related]
6. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin.
Graham RK; Deng Y; Slow EJ; Haigh B; Bissada N; Lu G; Pearson J; Shehadeh J; Bertram L; Murphy Z; Warby SC; Doty CN; Roy S; Wellington CL; Leavitt BR; Raymond LA; Nicholson DW; Hayden MR
Cell; 2006 Jun; 125(6):1179-91. PubMed ID: 16777606
[TBL] [Abstract][Full Text] [Related]
7. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
[TBL] [Abstract][Full Text] [Related]
8. Interaction of postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in the yeast artificial chromosome mouse model of Huntington's disease.
Fan J; Cowan CM; Zhang LY; Hayden MR; Raymond LA
J Neurosci; 2009 Sep; 29(35):10928-38. PubMed ID: 19726651
[TBL] [Abstract][Full Text] [Related]
9. P38 MAPK is involved in enhanced NMDA receptor-dependent excitotoxicity in YAC transgenic mouse model of Huntington disease.
Fan J; Gladding CM; Wang L; Zhang LY; Kaufman AM; Milnerwood AJ; Raymond LA
Neurobiol Dis; 2012 Mar; 45(3):999-1009. PubMed ID: 22198502
[TBL] [Abstract][Full Text] [Related]
10. Progressive phenotype and nuclear accumulation of an amino-terminal cleavage fragment in a transgenic mouse model with inducible expression of full-length mutant huntingtin.
Tanaka Y; Igarashi S; Nakamura M; Gafni J; Torcassi C; Schilling G; Crippen D; Wood JD; Sawa A; Jenkins NA; Copeland NG; Borchelt DR; Ross CA; Ellerby LM
Neurobiol Dis; 2006 Feb; 21(2):381-91. PubMed ID: 16150600
[TBL] [Abstract][Full Text] [Related]
11. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions.
Slow EJ; Graham RK; Osmand AP; Devon RS; Lu G; Deng Y; Pearson J; Vaid K; Bissada N; Wetzel R; Leavitt BR; Hayden MR
Proc Natl Acad Sci U S A; 2005 Aug; 102(32):11402-7. PubMed ID: 16076956
[TBL] [Abstract][Full Text] [Related]
12. Caspase cleavage of mutant huntingtin precedes neurodegeneration in Huntington's disease.
Wellington CL; Ellerby LM; Gutekunst CA; Rogers D; Warby S; Graham RK; Loubser O; van Raamsdonk J; Singaraja R; Yang YZ; Gafni J; Bredesen D; Hersch SM; Leavitt BR; Roy S; Nicholson DW; Hayden MR
J Neurosci; 2002 Sep; 22(18):7862-72. PubMed ID: 12223539
[TBL] [Abstract][Full Text] [Related]
13. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice.
Bradford J; Shin JY; Roberts M; Wang CE; Sheng G; Li S; Li XJ
J Biol Chem; 2010 Apr; 285(14):10653-61. PubMed ID: 20145253
[TBL] [Abstract][Full Text] [Related]
14. Transgenic mice expressing mutated full-length HD cDNA: a paradigm for locomotor changes and selective neuronal loss in Huntington's disease.
Reddy PH; Charles V; Williams M; Miller G; Whetsell WO; Tagle DA
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1035-45. PubMed ID: 10434303
[TBL] [Abstract][Full Text] [Related]
15. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease.
Van Raamsdonk JM; Pearson J; Murphy Z; Hayden MR; Leavitt BR
BMC Neurosci; 2006 Dec; 7():80. PubMed ID: 17147801
[TBL] [Abstract][Full Text] [Related]
16. Cellular and subcellular localization of Huntingtin [corrected] aggregates in the brain of a rat transgenic for Huntington disease.
Petrasch-Parwez E; Nguyen HP; Löbbecke-Schumacher M; Habbes HW; Wieczorek S; Riess O; Andres KH; Dermietzel R; Von Hörsten S
J Comp Neurol; 2007 Apr; 501(5):716-30. PubMed ID: 17299753
[TBL] [Abstract][Full Text] [Related]
17. Caspase-6-Resistant Mutant Huntingtin Does not Rescue the Toxic Effects of Caspase-Cleavable Mutant Huntingtin in vivo.
Graham RK; Deng Y; Pouladi MA; Vaid K; Ehrnhoefer D; Southwell AL; Bissada N; Franciosi S; Hayden MR
J Huntingtons Dis; 2012; 1(2):243-60. PubMed ID: 25063333
[TBL] [Abstract][Full Text] [Related]
18. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice.
Gray M; Shirasaki DI; Cepeda C; André VM; Wilburn B; Lu XH; Tao J; Yamazaki I; Li SH; Sun YE; Li XJ; Levine MS; Yang XW
J Neurosci; 2008 Jun; 28(24):6182-95. PubMed ID: 18550760
[TBL] [Abstract][Full Text] [Related]
19. Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity.
Luo S; Vacher C; Davies JE; Rubinsztein DC
J Cell Biol; 2005 May; 169(4):647-56. PubMed ID: 15911879
[TBL] [Abstract][Full Text] [Related]
20. Polyglutamine-modulated striatal calpain activity in YAC transgenic huntington disease mouse model: impact on NMDA receptor function and toxicity.
Cowan CM; Fan MM; Fan J; Shehadeh J; Zhang LY; Graham RK; Hayden MR; Raymond LA
J Neurosci; 2008 Nov; 28(48):12725-35. PubMed ID: 19036965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
